| abstract |
Embodiments of the present application relate to live attenuated alphavirus compositions and methods for live attenuated alphaviruses. The live attenuated virus composition includes, but is not limited to, one or more live attenuated alphaviruses and a composition that reduces inactivation and / or degradation of the live attenuated alphavirus. In other embodiments, the live attenuated virus composition may be a vaccine composition. In yet other compositions, the live attenuated alphavirus composition may comprise a HEPES buffer. In other embodiments, the HEPES buffer may further comprise carbohydrate and gelatin and / or salt. [Selection] Figure 5 |